Collectively, these findings position Gal-3 as a valuable predictive biomarker and a promising therapeutic target in both acute and chronic kidney diseases, with implications for early diagnosis, risk stratification, and development of personalized treatment strategies. Here, LGALS3 is linked to chronic kidney disease.